danshen (Salvia miltiorrhiza)

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• acne [Insufficient Evidence]
• angina [Insufficient Evidence]
• angina, unstable [Insufficient Evidence]
• atopic dermatitis (eczema) [Insufficient Evidence]
• cancer [Insufficient Evidence]
• cirrhosis [Insufficient Evidence]
• coronary heart disease [Insufficient Evidence]
• diabetes [Insufficient Evidence]
• diabetic foot ulcers [Insufficient Evidence]
• diabetic nephropathy [Insufficient Evidence]
• diabetic retinopathy [Insufficient Evidence]
• endometriosis [Insufficient Evidence]
• heart failure [Insufficient Evidence]
• hepatitis [Insufficient Evidence]
• HTN [Insufficient Evidence]
• HTN, pregnancy-induced [Insufficient Evidence]
• hyperlipidemia [Insufficient Evidence]
• hypoparathyroidism [Insufficient Evidence]
• intrauterine adhesion [Insufficient Evidence]
• kidney transplant [Insufficient Evidence]
• obesity [Insufficient Evidence]
• oral submucous fibrosis [Insufficient Evidence]
• pancreatitis [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• pre-eclampsia [Insufficient Evidence]
• psoriasis [Insufficient Evidence]
• stroke [Insufficient Evidence]
• venous thromboembolism prophylaxis [Insufficient Evidence]
• wound healing [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

angina

[Insufficient Evidence]

Dose: 216-270 mg PO tid; Alt: 250 mg/250 mL IV qd x10-14 days

angina, unstable

[Insufficient Evidence]

Dose: 0.4 g PO tid

coronary heart disease

[Insufficient Evidence]

Dose: 240-400 mg PO tid; Info: used with or without aspirin

diabetic retinopathy

[Insufficient Evidence]

Dose: 270-810 mg PO tid; Alt: 5 mg PO tid

heart failure

[Insufficient Evidence]

Dose: 400-1600 mL (75% extract) PO qd; Info: used with conventional tx

HTN

[Insufficient Evidence]

Dose: 450 mg PO bid; Info: used with antihypertensive tx

stroke

[Insufficient Evidence]

Dose: 270 mg PO tid

venous thromboembolism prophylaxis

[Insufficient Evidence]

Dose: 108 mg PO tid